<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.0//EN" "http://www.ncbi.nlm.nih.gov:80/entrez/query/static/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>Science and Education Publishing</PublisherName>
<JournalTitle>American Journal of Medical Case Reports</JournalTitle>
<Volume>2</Volume>
<Issue>8</Issue>
<PubDate PubStatus="epublish">
<Year>2014</Year>
<Month>08</Month>
<Day>13</Day>
</PubDate>
</Journal>
<ArticleTitle>Primary Pulmonary Lymphoma with Metastases - A Rare Presentation</ArticleTitle>
<FirstPage>149</FirstPage>
<LastPage>151</LastPage>
<Language>EN</Language>
<AuthorList>
<Author>
<FirstName>Sumiti</FirstName>
<LastName>Gupta</LastName>
</Author>
<Author>
<FirstName>Pansi</FirstName>
<LastName>Gupta</LastName>
<Affiliation>Department of Pathology, Pt. BDS PGIMS, Rohtak, Haryana, India</Affiliation>
</Author>
<Author>
<FirstName>Rajneesh</FirstName>
<LastName>Kalra</LastName>
</Author>
<Author>
<FirstName>Meenu</FirstName>
<LastName>Gill</LastName>
</Author>
<Author>
<FirstName>Atulya</FirstName>
<LastName>Atreja</LastName>
</Author>
<Author>
<FirstName>Dhruva</FirstName>
<LastName>Chaudhary</LastName>
</Author>

</AuthorList>
<ArticleIdList>
<ArticleId IdType="pii">AJMCR2014281</ArticleId>
<ArticleId IdType="doi">10.12691/ajmcr-2-8-1</ArticleId>
</ArticleIdList>
<History>
<PubDate PubStatus="received">
<Year>2014</Year>
<Month>07</Month>
<Day>18</Day>
</PubDate>
<PubDate PubStatus="revised">
<Year>2014</Year>
<Month>08</Month>
<Day>10</Day>
</PubDate>
<PubDate PubStatus="accepted">
<Year>2014</Year>
<Month>08</Month>
<Day>13</Day>
</PubDate>
</History>
<Abstract>Primary pulmonary non-Hodgkin's lymphoma is a very rare neoplasm. It is represented most commonly by marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type. We here in report a case of 64 year old male presented with a lung mass that was diagnosed to be NHL, with metastases to liver and kidney. It represents only 3-4% of extranodal NHL, less than 1% of NHL, and only 0.5- 1% of primary pulmonary malignancies. Current treatment options are surgery, chemotherapy, and radiotherapy.</Abstract>
</Article>
</ArticleSet>
